Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 51
  • Journal CiteScore: 10.69
  • Journal Impact Factor: 9.13
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Effects of l-arginine Supplementation in Patients with COVID Disease and Possible Role of GH/IGF-I Axis in Regulating Immune Response: Preliminary Results

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Grasso LFS, Romano O, Conticelli M, Muscariello R, Peirce C, Ippolito S, Sepe C, Massaro M,  

UOSD Malattie Endocrine Del Ricambio e Della Nutrizione, Ospedale del Mare ASL Napoli, Italy
UOC Patologia Clinica, Ospedale del Mare, ASL NapolI1, Italy

Posters & Accepted Abstracts: Health Sci J


Background and aim: Recent studies have suggested a possible link between GH-IGF-I axis impairment and COVID-19 disease (COVD) severity, reporting a potential beneficial effect of the administration of GH secretagogues in the high-risk groups. The current study aims at investigating retrospectively the effects of L-arginine supplementation in patients with COVD in addition to standard therapy, evaluating a possible role of GH/IGF-I axis in regulating immune response. Patients and methods: A total of 15 patients admitted to the COVID Center (4 F/11 M, mean age 58.9 years) entered the present study. All patients were treated for a mean time of 10.8 days with L-arginine supplementation. Disease severity, inflammatory response and GH/IGF-I levels were evaluated before and after therapy. Results: At baseline evaluation 5 patients (33%) had severe pneumonia associated with severe disease and 4 out of 5 patients (80%) had low IGF-I levels. Seven had moderate pneumonia (46%) associated with normal IGF-I levels, and 3 had mild pneumonia (20%), 1 out of 3 patients had low IGF-I levels. 11 patients were on O2 supplementations (73%). After L-arginine therapy, IGF-I levels increased significantly (p=0.001), and CRP, procalcitonin, fibrinogen, ferritin, d-dimers, WBC and lymphocyte levels reduced significantly (p=0.0001). Five patients were still treated with O2 supplementation (33%). Discussion: The results of the present study suggest that severe COVD should be associated with low GH/IGF-I levels and L-arginine could have a beneficial effect, in addition to standard therapy, in improving patient’s outcome.